Premium
Management of movement disorders in glutaryl‐CoA dehydrogenase deficiency: Anticholinergic drugs and botulinum toxin as additional therapeutic options
Author(s) -
Burlina A. P.,
Zara G.,
Hoffmann G. F.,
Zschocke J.,
Burlina A. B.
Publication year - 2004
Publication title -
journal of inherited metabolic disease
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.462
H-Index - 102
eISSN - 1573-2665
pISSN - 0141-8955
DOI - 10.1023/b:boli.0000045776.50573.52
Subject(s) - anticholinergic , medicine , botulinum toxin , movement disorders , anticholinergic agents , toxin , pharmacology , anesthesia , biology , disease , biochemistry
Summary : Glutaric aciduria type I is an inborn error of metabolism due to the deficiency of glutaryl‐CoA dehydrogenase, an enzyme responsible for the catabolism of lysine, hydroxylysine and tryptophan. The most important neurological symptoms include dyskinesia and dystonia, which can be focal, segmental or generalized. Treatment of the extrapyramidal syndrome is often unsatisfactory. We report our experience in the treatment of generalized and focal dystonia with anticholinergic drugs and botulinum toxin type A, respectively. Both therapies proved beneficial.